Neurodevelopmental and Growth Follow-Up of an Infant Exposed to Rosuvastatin by Lactation: A Case Report

<b><i>Background:</i></b> Usage of some medications while breastfeeding is supported with many clinical studies and proven to be safe for the mother-infant dyad, whereas knowledge on many medications' safety depends on pharmacokinetic data that are supported with only case series of real-life results. As data on rosuvastatin usage are limited, we present our case report with safe use of rosuvastatin in a breastfeeding mother of a 13-month-old infant. <b><i>Case:</i></b> Pretreatment assessments of the infant were performed. Complete blood count, kidney, and liver function tests were normal. The infant's lipid profile was evaluated before starting the mother's treatment, at 1 month of treatment, and at the fifth month of treatment in which the infant reached 18 months of age. All three evaluations resulted in normal ranges. At the 18-month follow-up of the infant of breastfeeding mother using rosuvastatin, no issues were detected in the child's development. <b><i>Conclusions:</i></b> In order for mothers with hypercholesterolemia not to neglect their own treatment while continuing to breastfeed, case reports should be included in the literature. In this case, it was shown that rosuvastatin treatment given to the mother did not affect the lipid profile and neurological development of the baby.